Nymox Pharmaceutical Corp. engages in the research and development of products for the aging population. The company is headquartered in Saint-Laurent, Quebec. The firm is focused on developing its drug candidate, Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The firm also has a patent portfolio covering its marketed products, its investigational drugs, as well as other therapeutic and diagnostic indications. The company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. Its products also include NicAlert and TobacAlert. NicAlert is a simple test to determine smoking status. The company is an easy-to-read test strip that can be used with either a saliva or a urine sample. TobacAlert is a home test that provides a quick, accurate, on-the-spot determination of a person’s level of exposure to tobacco products, including second-hand smoke.

Industry: In Vitro & In Vivo Diagnostic Substances Peers: Edesa Biotech Inc Xenon Pharmaceuticals Inc